ConductScience.org, home

Paper39997697

From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.

Porada M and 1 other. Metabolites, 2025. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension. Papers, record 39997697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39997697

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.
PubMed
Journal
Metabolites
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
2.19, provisional
iCite
Revised in PubMed
2025-02-27
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Porada MMichałhttps://orcid.org/0009-0009-8378-435X
2Bułdak ŁŁukaszhttps://orcid.org/0000-0002-2017-5516

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
BNW-1-157/N/4/KMedical University of SilesiaPubMed

Source PubMed

Download CSV of grants

References359

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126656007Associations between the tumor necrosis factor-α gene and interleukin-10 gene polymorphisms and risk of alcoholic liver disease: A meta-analysis.Clin Res Hepatol Gastroenterol2016https://conductscience.org/library/papers/26656007PubMed
238906512Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension.Gastroenterology2024https://conductscience.org/library/papers/38906512PubMed
319157625Angiogenesis in liver disease.J Hepatol2009https://conductscience.org/library/papers/19157625PubMed
434165199Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension.Aliment Pharmacol Ther2021https://conductscience.org/library/papers/34165199PubMed
533804385PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center.J Pers Med2021https://conductscience.org/library/papers/33804385PubMed
64924592Hepatic fibrosis. Correlation of biochemical and morphologic investigations.Am J Med1970https://conductscience.org/library/papers/4924592PubMed
726573697How to effectively manage the event of bleeding complications when using anticoagulants.Expert Rev Hematol2016https://conductscience.org/library/papers/26573697PubMed
824134058Beta-blockers in portal hypertension: new developments and controversies.Liver Int2014https://conductscience.org/library/papers/24134058PubMed
922806357Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent.Hepatology2012https://conductscience.org/library/papers/22806357PubMed
1032302598Statins and PCSK9 inhibitors: A new lipid-lowering therapy.Eur J Pharmacol2020https://conductscience.org/library/papers/32302598PubMed
1131893957PCSK9 inhibitors for treating hypercholesterolemia.Expert Opin Pharmacother2020https://conductscience.org/library/papers/31893957PubMed
1227332721Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.Dig Dis2016https://conductscience.org/library/papers/27332721PubMed
1314687169A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis.Aliment Pharmacol Ther2004https://conductscience.org/library/papers/14687169PubMed
1431705824Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.Hepatology2020https://conductscience.org/library/papers/31705824PubMed
1517016424Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.Nat Rev Drug Discov2006https://conductscience.org/library/papers/17016424PubMed
1626406236Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis.PLoS One2015https://conductscience.org/library/papers/26406236PubMed
1717336417AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers.J Hepatol2007https://conductscience.org/library/papers/17336417PubMed
1825309079Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.World J Gastroenterol2014https://conductscience.org/library/papers/25309079PubMed
1926412302Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.Sci Rep2015https://conductscience.org/library/papers/26412302PubMed
2029331339Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.J Hepatol2018https://conductscience.org/library/papers/29331339PubMed

See all 359 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42279197Longitudinal Inpatient Trajectories After Splenic Artery Embolization in Cirrhosis: Real-World Evidence from Kazakhstan.J Clin Med2026https://conductscience.org/library/papers/42279197PubMed
41278477Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications.Front Cell Infect Microbiol2025https://conductscience.org/library/papers/41278477PubMed
41210055Liver Cirrhosis in Pregnancy and Its Fetal Outcomes: A Prospective Case Series.Cureus2025https://conductscience.org/library/papers/41210055PubMed
41105553Pharmacological Management for Prevention and Treatment of Posthepatectomy Liver Failure.Dig Surg2025https://conductscience.org/library/papers/41105553PubMed
40784797[Research progress on early-stage primary biliary cholangitis accompanied by portal hypertension].Zhonghua Gan Zang Bing Za Zhi2025https://conductscience.org/library/papers/40784797PubMed
40591004TEAD4-mediated upregulation of LPAR3 augments hepatic stellate cell activation in portal hypertension.Cell Biol Toxicol2025https://conductscience.org/library/papers/40591004PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39997697

GET https://conductscience.org/api/papers/v1/39997697/references?page=2